Daratumumab

Daratumumab 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Multiple Myeloma、Smoldering Multiple Myeloma、Immunoglobulin Light-chain Amyloidosis。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 Daratumumab 研究

• Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma

  II 期招募中美国NCT05896228

• Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.

  II 期招募中意大利NCT04915248

• Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma

  III 期招募中美国NCT07772024

• Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

  II 期招募中美国NCT04991103

• A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma

  I 期招募中美国澳大利亚中国GeorgiaNCT07477587

• A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

  III 期招募中美国Argentina澳大利亚奥地利NCT05623020

• Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

  III 期招募中美国NCT06022939

• A Study of Anti-CD38 Monoclonal Antibody (SG301) Subcutaneous Injection in Children With Nephrotic Syndrome With Frequent Relapses or Steroid Dependence

  II 期招募中中国NCT07087314

• Anti-CD38 Antibody Treating Elderly Patients With Primary Immune Thrombocytopenia (ITP)

  II 期招募中中国NCT07063199

• Escalation of Doses of Daratumumab in Combination With Chemotherapy (Idarubicin and Cytarabine or CPX-351) in Patients of 60 Years Old or More With Adverse Risk Acute Myeloblastic Leukemia (AML) (DARALAM)

  I 期招募中法国NCT05749276

• Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST)

  II 期招募中西班牙NCT07045909

• A Prospective Study Comparing DRd With VRd-lite in Elderly Newly Diagnosed Multiple Myeloma

  不适用招募中中国NCT06497738

• Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure

  早期 I 期招募中美国NCT06142396

• Plan Development for Giving Teclistamab in the Outpatient Setting

  IV 期招募中加拿大NCT06251076

• A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

  I 期 / II 期招募中美国澳大利亚比利时法国NCT06953960

• 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

  I 期招募中美国NCT06287944

• A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)

  III 期招募中中国NCT06464991

• Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse

  II 期招募中美国NCT06827860

• An Investigator-Initiated, Phase II, Multicenter, Open-Label, Single-Arm, Prospective Clinical Trial to Evaluate the Efficacy and Safety of Alternating Bortezomib-Based Regimens in Combination With DaratUMumab Followed by Maintenance With Daratumumab in the Frontline Setting of Primary Plasma CEll L

  II 期招募中GreeceNCT06636552

• A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).

  II 期招募中中国NCT07638683

• Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection

  IV 期招募中中国NCT06409702

• Multi-target Drugs Sequential Combination Therapy in Adults Patients With Newly Diagnosed Primary Immune Thrombocytopenia

  IV 期招募中中国NCT07788456

• Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

  III 期招募中美国澳大利亚Brazil加拿大NCT07555938

• A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma

  II 期招募中美国NCT04661137

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。